111In-DOTA-OX40 mAb

N/A

Report date: 2025/10/31 15:08:08

Base Information

Drug Name111In-DOTA-OX40 mAb
Drug Alias NameN/A
ClassificationRadiation-emitting products > Nuclides > Indium > 111InRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionTumor necrosis factor receptor superfamily member 4 binders
TargetsTumor necrosis factor receptor superfamily member 4
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCheng-Hsin General HospitalNational Defense Medical Center, Taiwan, China
China Registration ClassN/A

Develop Information

Active CompaniesNational Defense Medical Center, Taiwan, ChinaCheng-Hsin General Hospital
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A